ArticleFrontiers in medicine2025
Thrombotic microangiopathy with irreversible renal function in a CKD patient following COVID-19: case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of chronic kidney disease (CKD), in a patient with normal renal function, diagnosed as acute renal failure stage 3 after coronavirus disease 2019 (COVID-19)-associated thrombotic microangiopathy (TMA) characterized by the presence of thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. The results of the renal biopsy were thickening of the small artery wall with mucous edema, endothelial swelling and hyperplasia, and segmental endothelial onion-like hyperplasia. However, the pathogenesis factors of the patient who suffered from COVID-19-associated TMA were not clear, although blood complements, activity of ADAMTS13, and Factor H were detected as normal. After the administration of pulse glucocorticoid, plasma exchange, and hemodialysis, the patient developed chronic renal failure and depended on peritoneal dialysis 12 months later. Although the clinical manifestations of TMA are similar, the etiology and pathogenesis are very complex. It is very important to determine the pathogenesis of TMA to proceed with precise treatment to improve the prognosis of the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.